Premium
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
Author(s) -
Lucchesi Alessandro,
Carloni Silvia,
De Matteis Serena,
Ghetti Martina,
Musuraca Gerardo,
Poggiaspalla Monica,
Augello Accursio F.,
Giordano Giulio,
Fattori Pier P.,
Martinelli Giovanni,
Napolitano Roberta
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16335
Subject(s) - platelet , fibrinogen , aspirin , medicine , myeloproliferative neoplasm , fibrin , platelet activation , receptor , flow cytometry , immunology , thrombocytosis , thrombin , endocrinology , gastroenterology , myelofibrosis , bone marrow
Summary This study was conducted to evaluate the expression of fibrinogen receptors on platelets of Philadelphia‐negative chronic myeloproliferative neoplasm (MPN) patients. We collected blood samples from 40 consecutive MPN patients and healthy volunteers. We performed flow cytometry analysis of P‐selectin expression and integrin beta‐3, activation of glycoprotein (GP) IIb/IIIa and fibrinogen receptor exposure (PAC‐1 binding). Surprisingly, we found a very low PAC‐1 binding capacity in MPN patients; however, the expression of PAC‐1 was almost completely recovered with aspirin intake. We hypothesize that the hypercoagulable states observed in MPN patients could depend on a primarily plasma‐driven impairment of fibrin turnover and thrombin generation.